5-Aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model

Clinical Cancer Research

Volumn 13, Issue 21, 2007, Pages 6527-6531

  Ikeda, Ikuko ^a   Tomimoto, Ayako ^a   Wada, Koichiro ^b   Fujisawa, Toshio ^a   Fujita, Koji ^a   Yonemitsu, Kyoko ^a   Nozaki, Yuichi ^a   Endo, Hiroki ^a   Takahashi, Hirokazu ^a   Yoneda, Masato ^a   Inamori, Masahiko ^a   Kubota, Kensuke ^a   Saito, Satoru ^a   Nagashima, Yoji ^a   Nakagama, Hitoshi ^c   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; COLITIS; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MESALAMINE; MICE; MODELS, BIOLOGICAL; NEOPLASMS; PPAR GAMMA; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 35948935272     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1208     Document Type: Article

References (16)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
2. Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 2002;8:356-61.
3. Rubon DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 2005;100:1345-53.
4. Seril DN, Liao J, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003;24:353-62.
5. Cooper HS, Murthy S, Kido K, Yoshitake H, Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, β-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000;21:757-68.
6. Suzuki R, Kohno H, Sugie S, Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci 2004;95:721-7.
7. Osawa E, Nakajima A, Wada K, et al. Peroxisome prolifarator-activated receptor-γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-7.
8. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-δ 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell 1995;83:803-12.
9. Kubota N, Terauchi Y, Miki H, et al. PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999;4:597-609.
10. Lefebvre AM, Auwerx J. PPARγ is induced during differentiation of colon epithelium cells. J Endocrinol 1999;162:331-40.
11. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.
12. Ward JM. Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Lab Invest 1974;30:505-13.
13. Watanabe I, Toyoda M, Okuda J, et al. Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Jpn J Cancer Res 1999;90:188-93.
14. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferators-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001;61:2424-8.
15. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
16. Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a cox-2 inhibitor and PPAR ligands. BMC Cancer 2005;5:46.